{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:23:30Z","timestamp":1790011410579,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Pfizer Inc"},{"name":"Pfizer Inc"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.joca.2017.01.006","type":"journal-article","created":{"date-parts":[[2017,1,21]],"date-time":"2017-01-21T00:30:48Z","timestamp":1484958648000},"page":"866-877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Identification of serological biomarker profiles associated with total joint replacement in osteoarthritis patients"],"prefix":"10.1016","volume":"25","author":[{"given":"R.H.G.P.","family":"Arends","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4764-5100","authenticated-orcid":false,"given":"M.A.","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Verburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.R.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Bay-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joca.2017.01.006_bib1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/ncprheum0193","article-title":"Prospects for disease modification in osteoarthritis","volume":"2","author":"Abramson","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.joca.2017.01.006_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00296-009-1183-1","article-title":"Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?","volume":"30","author":"Bay-Jensen","year":"2010","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.joca.2017.01.006_bib3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/ard.2003.007302","article-title":"Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis","volume":"63","author":"Gineyts","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2017.01.006_bib4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1136\/annrheumdis-2013-204111","article-title":"The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?","volume":"73","author":"Karsdal","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2017.01.006_bib5","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2434","article-title":"Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity","volume":"10","author":"Karsdal","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.joca.2017.01.006_bib6","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/1529-0131(199906)42:6<1159::AID-ANR12>3.0.CO;2-Q","article-title":"Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions","volume":"42","author":"Manicourt","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2017.01.006_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.joca.2013.10.018","article-title":"Osteoarthritis \u2013 a case for personalized health care?","volume":"22","author":"Karsdal","year":"2014","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2017.01.006_bib8","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1136\/annrheumdis-2013-203726","article-title":"Value of biomarkers in osteoarthritis: current status and perspectives","volume":"72","author":"Lotz","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2017.01.006_bib9","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2217\/bmm.13.144","article-title":"Biomarkers of cartilage and surrounding joint tissue","volume":"8","author":"Siebuhr","year":"2014","journal-title":"Biomark Med"},{"key":"10.1016\/j.joca.2017.01.006_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13547500902777608","article-title":"Biochemical markers and the FDA critical path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development","volume":"14","author":"Karsdal","year":"2009","journal-title":"Biomarkers"},{"key":"10.1016\/j.joca.2017.01.006_bib11","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/1529-0131(200110)44:10<2242::AID-ART386>3.0.CO;2-F","article-title":"Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis","volume":"44","author":"Boers","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2017.01.006_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/03008207509152192","article-title":"Type III collagen: a major constituent of rheumatoid and normal human synovial membrane","volume":"4","author":"Eyre","year":"1975","journal-title":"Connect Tissue Res"},{"key":"10.1016\/j.joca.2017.01.006_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1755-1536-7-4","article-title":"The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?","volume":"7","author":"Genovese","year":"2014","journal-title":"Fibrogenes Tissue Repair"},{"key":"10.1016\/j.joca.2017.01.006_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/apt.12820","article-title":"Review article: the efficacy of biomarkers in chronic fibroproliferative diseases \u2013 early diagnosis and prognosis, with liver fibrosis as an exemplar","volume":"40","author":"Karsdal","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.joca.2017.01.006_bib15","doi-asserted-by":"crossref","first-page":"G807","DOI":"10.1152\/ajpgi.00447.2014","article-title":"Novel insights into the function and dynamics of extracellular matrix in liver fibrosis","volume":"308","author":"Karsdal","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.joca.2017.01.006_bib16","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3109\/1354750X.2011.620628","article-title":"A\u00a0novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M)","volume":"16","author":"Leeming","year":"2011","journal-title":"Biomarkers"},{"key":"10.1016\/j.joca.2017.01.006_bib17","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/art.37843","article-title":"Circulating citrullinated vimentin fragments reflect disease burden in ankylosing spondylitis and have prognostic capacity for radiographic progression","volume":"65","author":"Bay-Jensen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2017.01.006_bib18","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s00296-011-2237-8","article-title":"Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study","volume":"32","author":"Bay-Jensen","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.joca.2017.01.006_bib19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.clinbiochem.2011.01.001","article-title":"Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM\u2013increased serum CIIM in subjects with severe radiographic osteoarthritis","volume":"44","author":"Bay-Jensen","year":"2011","journal-title":"Clin Biochem"},{"key":"10.1016\/j.joca.2017.01.006_bib20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.semarthrit.2013.07.008","article-title":"Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study","volume":"43","author":"Bay-Jensen","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.joca.2017.01.006_bib21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1089\/adt.2009.0199","article-title":"Biochemical markers of joint tissue turnover","volume":"8","author":"Bay-Jensen","year":"2010","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.joca.2017.01.006_bib22","doi-asserted-by":"crossref","first-page":"e54504","DOI":"10.1371\/journal.pone.0054504","article-title":"Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis","volume":"8","author":"Bay-Jensen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.joca.2017.01.006_bib23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2012-eular.1810","article-title":"Identification of serological biomarker profiles associated with early response to tocilizumab in rheumatoid arthritis","volume":"71","author":"Bay-Jensen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2017.01.006_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.joca.2013.10.020","article-title":"Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover","volume":"22","author":"Siebuhr","year":"2014","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2017.01.006_bib25","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1136\/annrheumdis-2012-203164","article-title":"Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial","volume":"73","author":"Balanescu","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2017.01.006_bib26","unstructured":"Bello A, Ekman E, Radin D, Davignon I, Smith M, Brown M, et\u00a0al. Long-term tanezumab treatment for osteoarthritis: efficacy and safety results. Presented at: American College of Rheumatology (ACR)\/Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting, Washington DC, November 9\u201314, 2012."},{"key":"10.1016\/j.joca.2017.01.006_bib27","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/art.37950","article-title":"Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase 3 trial","volume":"65","author":"Brown","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2017.01.006_bib28","unstructured":"Brown MT, Litchy WJ, Herrmann DN, Goldstein M, Burr AM, Smith MD, et\u00a0al. Peripheral nerve function following 24-weeks treatment with tanezumab, a nerve growth factor (NGF) inhibitor. Presented at: 16th Congress of the European Federation of Neurological Societies, Stockholm, Sweden, September 8\u201311, 2012."},{"key":"10.1016\/j.joca.2017.01.006_bib29","first-page":"790","article-title":"Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial","volume":"13","author":"Brown","year":"2012","journal-title":"J\u00a0Pain"},{"key":"10.1016\/j.joca.2017.01.006_bib30","first-page":"373","article-title":"Anti-nerve growth factor in pain management: current evidence","volume":"9","author":"Chang","year":"2016","journal-title":"J\u00a0Pain Res"},{"key":"10.1016\/j.joca.2017.01.006_bib31","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3899\/jrheum.131294","article-title":"Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen","volume":"41","author":"Ekman","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2017.01.006_bib32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.39492","article-title":"When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the tanezumab clinical development program","volume":"68","author":"Hochberg","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.joca.2017.01.006_bib33","series-title":"Tanezumab Arthritis Advisory Committee: Briefing Document","author":"Pfizer Inc","year":"2012"},{"key":"10.1016\/j.joca.2017.01.006_bib34","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/annrheumdis-2013-204905","article-title":"Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain","volume":"74","author":"Schnitzer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2017.01.006_bib35","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.pain.2013.04.035","article-title":"A\u00a0phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee","volume":"154","author":"Spierings","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.joca.2017.01.006_bib36","unstructured":"Tive L, Dabezies EJ, Fountaine RJ, Brown MT, Smith MD, West CR, et\u00a0al. Long-term safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis (NCT00994890). Presented at: American College of Rheumatology (ACR)\/Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting, San Diego, CA, October 26\u201330, 2013."},{"key":"10.1016\/j.joca.2017.01.006_bib37","series-title":"Classification and Regression Trees","author":"Breiman","year":"1984"},{"issue":"1997","key":"10.1016\/j.joca.2017.01.006_bib38","article-title":"An introduction to recursive partitioning using the RPART routines","volume":"61","author":"Thernau","year":"1997","journal-title":"Divsion Biostat"},{"key":"10.1016\/j.joca.2017.01.006_bib39","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.spl.2005.08.034","article-title":"Confidence regions for the ratio of percentiles","volume":"76","author":"Huang","year":"2006","journal-title":"Statistics Probab Lett"},{"key":"10.1016\/j.joca.2017.01.006_bib40","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.joca.2017.01.006_bib41","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F","article-title":"Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians","volume":"19","author":"Carpenter","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/j.joca.2017.01.006_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinforma"},{"key":"10.1016\/j.joca.2017.01.006_bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2011-201177","article-title":"Associations of CTX-II with biochemical markers of bone turnover raise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis","volume":"72","author":"van Spil","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2017.01.006_bib44","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.joca.2014.09.003","article-title":"Systemic biochemical markers of joint metabolism and inflammation in relation to radiographic parameters and pain of the knee: data from CHECK, a cohort of early-osteoarthritis subjects","volume":"23","author":"Van Spil","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2017.01.006_bib45","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.joca.2015.03.023","article-title":"The ability of systemic biochemical markers to reflect presence, incidence, and progression of early-stage radiographic knee and hip osteoarthritis: data from CHECK","volume":"23","author":"Van Spil","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2017.01.006_bib46","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.joca.2012.08.001","article-title":"Cross-sectional and predictive associations between plasma adipokines and radiographic signs of early-stage knee osteoarthritis: data from CHECK","volume":"20","author":"Van Spil","year":"2012","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2017.01.006_bib47","series-title":"The Osteoarthritis Initiative: Protocol for the Cohort Study","author":"Nevitt","year":"2006"},{"key":"10.1016\/j.joca.2017.01.006_bib48","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/BOR.0b013e32836200b8","article-title":"NSAIDs and fracture healing","volume":"25","author":"Geusens","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.joca.2017.01.006_bib49","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00198-011-1692-0","article-title":"Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS)","volume":"23","author":"Vestergaard","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.joca.2017.01.006_bib50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1472-6904-8-12","article-title":"Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin","volume":"8","author":"Karsdal","year":"2008","journal-title":"BMC Clin Pharmacol"}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458417300316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458417300316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:45:29Z","timestamp":1761018329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1063458417300316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1063458417300316"],"URL":"https:\/\/doi.org\/10.1016\/j.joca.2017.01.006","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727237664.793533829","asserted-by":"object"}]},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of serological biomarker profiles associated with total joint replacement in osteoarthritis patients","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joca.2017.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Osteoarthritis Research Society International. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}